A transaction that reaches beyond one clinical asset
On 31 August 2026, Lilly and Merida announced a definitive acquisition agreement with total cash consideration of up to $2.875 billion, including an upfront payment and contingent milestones. Closing is expected in the fourth quarter of 2026, subject to regulatory approval and other customary conditions.
Merida is not positioned as a conventional broad immunosuppression platform. Its engineered biologics are designed to selectively identify, capture and eliminate pathogenic antibodies while preserving normal immune function. Lilly's announcement identifies MER511 as a Phase 1 program in Graves' disease. The NEXUS study registered on ClinicalTrials.gov is evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity.
How precision clearance works: recognition, delivery and degradation
Platforms in this class typically combine a disease-relevant antigen or antibody-binding module with an engineered Fc or a module engaging a hepatic receptor. The candidate first captures its target antibody in circulation. The resulting complex can then engage endogenous clearance routes such as FcγRIIB on liver sinusoidal endothelial cells or ASGPR on hepatocytes, promoting cellular uptake and lysosomal degradation.
The central proposition is molecular selectivity. Compared with depleting a broad B-cell population or chronically suppressing multiple immune pathways, precision clearance may limit effects on protective antibodies and normal immune surveillance. Human studies still need to establish the depth and durability of clearance, immunogenicity and long-term safety.
From PLA2R to Gd-IgA1: kidney disease is an important test bed
Merida has disclosed an early program in membranous nephropathy focused on anti-PLA2R autoantibodies. It illustrates why antibody-mediated kidney diseases are attractive settings for the “remove the circulating driver—reduce renal deposition and injury” hypothesis: pathogenic antibodies can be directly measured, and their levels may provide a quantitative pharmacodynamic window.
In IgA nephropathy, Gd-IgA1, related autoantibodies and immune complexes form a key upstream pathogenic axis. Directly recognizing and removing circulating drivers represents a disease-modifying concept distinct from blocking downstream inflammation alone. Target structure, complex composition, tissue distribution and clearance kinetics differ by disease, so portability must be demonstrated program by program.
Industry implication: platform value depends on a complete evidence chain
The proposed transaction brings greater attention to precision antibody clearance, but cross-indication scalability will depend on closing the loop between molecular design, receptor biology, pharmacokinetics, patient selection and clinical endpoints. Measurable circulating pathogenic factors and renal injury markers make kidney disease a compelling environment in which to build that evidence chain.
From industry signal to internal R&D validation
This industry event highlights the importance of connecting selectivity, pharmacokinetics, biomarkers and clinical endpoints into an evidence chain. Podigy will continue advancing multiple therapeutic modalities and experimental-validation platforms for kidney diseases; the specific targets, molecular structures and mechanisms of Podigy's own candidates are undisclosed. Third-party targets and mechanisms discussed in this article come from public industry information and do not represent Podigy's pipeline.
The acquisition remains subject to regulatory approval and customary closing conditions. Lilly and Merida have referenced preliminary Phase 1 observations for MER511, while formal study results have not yet been posted on ClinicalTrials.gov; full clinical data and peer-reviewed evidence remain necessary. Merida's platform, patents and candidates are independent of Podigy Biopharma. This article is an industry perspective and not medical or investment advice.